"Biomarkers, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS.
Descriptor ID |
D014408
|
MeSH Number(s) |
D23.101.140
|
Concept/Terms |
Biomarkers, Tumor- Biomarkers, Tumor
- Tumor Biomarkers
- Markers, Biological Tumor
- Tumor Markers, Biological
- Markers, Tumor Metabolite
- Tumor Metabolite Markers
- Metabolite Markers, Tumor
- Marker, Tumor Metabolite
- Metabolite Marker, Tumor
- Tumor Metabolite Marker
- Tumor Markers, Biologic
- Biologic Tumor Markers
- Markers, Biologic Tumor
- Marker, Biologic Tumor
- Biologic Tumor Marker
- Tumor Marker, Biologic
- Biochemical Tumor Markers
- Markers, Biochemical Tumor
- Marker, Biochemical Tumor
- Biochemical Tumor Marker
- Tumor Marker, Biochemical
- Tumor Markers, Biochemical
- Carcinogen Markers
- Markers, Carcinogen
- Markers, Neoplasm Metabolite
- Neoplasm Metabolite Markers
- Marker, Neoplasm Metabolite
- Metabolite Marker, Neoplasm
- Neoplasm Metabolite Marker
- Metabolite Markers, Neoplasm
- Biological Tumor Markers
- Biological Tumor Marker
- Tumor Marker, Biological
- Marker, Biological Tumor
Markers, Tumor- Markers, Tumor
- Tumor Markers
- Biomarkers, Cancer
- Cancer Biomarkers
|
Below are MeSH descriptors whose meaning is more general than "Biomarkers, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Tumor".
This graph shows the total number of publications written about "Biomarkers, Tumor" by people in this website by year, and whether "Biomarkers, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 17 | 9 | 26 |
1995 | 15 | 7 | 22 |
1996 | 11 | 14 | 25 |
1997 | 14 | 14 | 28 |
1998 | 22 | 26 | 48 |
1999 | 21 | 26 | 47 |
2000 | 19 | 32 | 51 |
2001 | 35 | 26 | 61 |
2002 | 33 | 36 | 69 |
2003 | 52 | 61 | 113 |
2004 | 69 | 56 | 125 |
2005 | 80 | 79 | 159 |
2006 | 79 | 78 | 157 |
2007 | 93 | 74 | 167 |
2008 | 96 | 70 | 166 |
2009 | 103 | 85 | 188 |
2010 | 86 | 119 | 205 |
2011 | 120 | 121 | 241 |
2012 | 122 | 116 | 238 |
2013 | 134 | 100 | 234 |
2014 | 147 | 100 | 247 |
2015 | 145 | 100 | 245 |
2016 | 154 | 135 | 289 |
2017 | 158 | 130 | 288 |
2018 | 113 | 135 | 248 |
2019 | 136 | 125 | 261 |
2020 | 136 | 128 | 264 |
2021 | 109 | 118 | 227 |
2022 | 7 | 95 | 102 |
2023 | 3 | 69 | 72 |
2024 | 2 | 27 | 29 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.
-
Mutational Signature Changes in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. Oncologist. 2024 Apr 04; 29(4):e475-e486.
-
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. Cell. 2024 Mar 28; 187(7):1617-1635.
-
A novel machine learning algorithm selects proteome signature to specifically identify cancer exosomes. Elife. 2024 Mar 26; 12.
-
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Clin Cancer Res. 2024 Mar 15; 30(6):1152-1159.
-
Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC. J Exp Clin Cancer Res. 2024 Mar 15; 43(1):81.
-
Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Gut. 2024 Mar 07; 73(4):639-648.
-
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design. Cancer Treat Rev. 2024 Apr; 125:102703.
-
Comprehensive Immunogenomic Profiling of IDH1-/2-Altered Cholangiocarcinoma. JCO Precis Oncol. 2024 Mar; 8:e2300544.
-
Investigating the Spatial Distribution of Proliferating Cells in Primary Ovarian Cancers. Discov Med. 2024 Mar; 36(182):632-645.
-
Circulating microRNA Panel for Prediction of Recurrence and Survival in Early-Stage Lung Adenocarcinoma. Int J Mol Sci. 2024 Feb 16; 25(4).